Juniper Pharmaceuticals, Inc. Common Stock
JNP
JNP was delisted on the 13th of August, 2018.
37 hedge funds and large institutions have $14.2M invested in Juniper Pharmaceuticals, Inc. Common Stock in 2014 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 7 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
43% more capital invested
Capital invested by funds: $9.93M → $14.2M (+$4.26M)
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
3% more funds holding
Funds holding: 36 → 37 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$388K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$298K |
| 3 |
PCM
Perritt Capital Management
Chicago,
Illinois
|
+$179K |
| 4 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
+$159K |
| 5 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
+$150K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DMK
David M. Knott
|
-$393K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$114K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$65K |
| 4 |
PP
PDT Partners
New York
|
-$60K |
| 5 |
ST
Spot Trading
Chicago,
Illinois
|
-$34K |
JNP Hedge Fund Activity: Q4 2014 in Review
37 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Juniper Pharmaceuticals, Inc. Common Stock (JNP) for Q4 2014, worth a combined $14.2M — up 43% from $9.93M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new JNP positions and 7 closed out — a net gain of 2 holders — while 10 added to existing stakes and 5 trimmed.
The largest buyer was Royal Bank of Canada, adding an estimated $388K. The largest seller was David M. Knott, exiting entirely with an estimated $393K sold.
- 37 institutional investors held Juniper Pharmaceuticals, Inc. Common Stock (JNP) as of Q4 2014, up from 36 in Q3 2014.
- Funds reported $14.2M of Juniper Pharmaceuticals, Inc. Common Stock stock for Q4 2014, up 43% quarter-over-quarter.
- 9 funds opened new Juniper Pharmaceuticals, Inc. Common Stock positions in Q4 2014 and 7 closed out, a net change of +2 holders.
- The largest Juniper Pharmaceuticals, Inc. Common Stock buyer in Q4 2014 was Royal Bank of Canada, an estimated $388K added.
- The largest Juniper Pharmaceuticals, Inc. Common Stock seller in Q4 2014 was David M. Knott, an estimated $393K sold.
Based on aggregated 13F filings for Q4 2014.